**Name of Journal: *World Journal of Gastrointestinal Endoscopy***

**ESPS Manuscript NO: 18441**

**Manuscript Type: MINIREVIEWS**

**Second-look endoscopy and factors associated with delayed bleeding after endoscopic submucosal dissection**

Kim SJ *et al.* Second-look endoscopy after ESD

**Su-Jin Kim, Cheol-Woong Choi, Dae-Hwan Kang, Hyung-Wook Kim,** **Su-Bum Park**

**Su-Jin Kim, Cheol-Woong Choi, Dae-Hwan Kang, Hyung-Wook Kim,** **Su-Bum Park,** Department of Internal Medicine, Pusan National University School of Medicine and Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan 626-770, South Korea

**Author contributions:** Kim SJ wrote the manuscript; Choi CW organized the manuscript; Kang DH and Kim HW, Park SB contributed to the design, organization, and draft of the manuscript; all authors read and approved the final manuscript.

**Conflict-of-interest statement:** The authors declare no conflict of interests.

**Open-Access:** This article is an open-access article which selected by an in-house editor and fully peer-reviewed by external reviewers. It distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Correspondence to: Cheol Woong Choi, MD,** Department of Internal Medicine, Medical Research Institute, Pusan National University School of Medicine and Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Beomeo-ri, Mulgeum-eup, Yangsan-si, Gyeongsangnam-do 626-770, South Korea. luckyace@hanmail.net

**Telephone:** +82-55-3601535

**Fax:** +82-55-3601536

**Received:** April 20, 2015

**Peer-review started:** April 21, 2015

**First decision:** September 8, 2015

**Revised:** October 1, 2015

**Accepted:** December 4, 2015

**Article in press:**

**Published online:**

**Abstract**

Endoscopic submucosal dissection (ESD) is a widely used procedure as curative treatment for superficial gastric neoplasms, including early gastric cancer (EGC) without lymph node metastasis. However, ESD requires advanced endoscopic skill and there is a major concern regarding complications from bleeding. So far, extensive efforts have been made to develop strategies to reduce post-ESD bleeding. Use of proton pump inhibitors and coagulating exposed vessels on the ulcer ﬂoor after ESD are strategies known to reduce the risk of delayed bleeding. Second-look endoscopy (SLE) is also carried out to reduce delayed bleeding following ESD in many institutions. However, the incidence of bleeding still remains around 5%, and further measures are needed to reduce delayed bleeding after gastric ESD. Recently, three randomized studies indicated that routine SLE was unnecessary. Although routine SLE may not be recommended for all patients after gastric ESD, SLE might be an important tool for the prevention of the delayed bleeding in selected high-risk patients. Thus, the identification of the risk factors, such as large size of resected specimen and treatment with multiple antiplatelet medications, may help to further guide clinicians in deciding whether to perform SLE. Studies carried out on larger cohorts are necessary to clarify the efficacy of SLE after ESD in the prevention of post-ESD bleeding in potentially high-risk patients.

**Key words:** Endoscopic submucosal dissection; Second-look endoscopy; Early gastric cancer

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Second-look endoscopy (SLE) for selected patients might be an important tool for the prevention of delayed bleeding following endoscopic submucosal dissection (ESD). Risk factors for bleeding after ESD include large size of resected specimen and use of multiple antiplatelet agents. In addition, submucosal fibrosis and nausea might be risk factors associated with high-risk ulcer stigmata. Such risk factors require further evaluation as to whether SLE is indicated.

Kim SJ, Choi CW, Kang DH, Kim HW, Park SB. Second-look endoscopy and factors associated with delayed bleeding after endoscopic submucosal dissection.*World J Gastrointest Endosc* 2015; In press

**INTRODUCTION**

In recent years, endoscopic submucosal dissection (ESD) for superﬁcial gastric epithelial neoplasms including early gastric cancer (EGC) has been commonly used in clinical practice in Asian countries. While a snare is used in conventional endoscopic mucosal resection (EMR), various types of endoscopic surgical knives are used in ESD for the purpose of mucosal incision and submucosal dissection. Therefore, this technique enables higher en bloc resection and histologic complete resection rates in patients with larger or ulcerated tumors[[1](#_ENREF_1),[2](#_ENREF_2)]. However, with ESD, concerns still exist regarding technical difﬁculties and a higher risk of complications, especially bleeding and perforation[[1](#_ENREF_1),[2](#_ENREF_2)]. Immediate intraoperative bleeding is easily recognized at the time of the procedure and can be treated endoscopically in most cases. However, delayed bleeding, manifesting as hematemesis or melena, may occur days after the procedure, occasionally even after discharge from hospital. The reported incidence of delayed bleeding after gastric ESD varies from 5.4% to 22%[[3-9](#_ENREF_3)]. As any delay in the recognition of such an event may result in serious cardiovascular complications, such as hypovolemic shock, prevention of delayed bleeding is an important clinical problem following ESD to address.

ESD causes large artificial ulcers, but there is no consensus regarding second-look endoscopy (SLE), and when or whether the procedure should be used. Although recent randomized studies demonstrated no benefit for the use of SLE in the prevention of post-ESD bleeding, a multicenter survey of patient management following gastric ESD demonstrated that SLE was utilized by most institutions[[9](#_ENREF_9)]. In the present review article, the optimal perioperative management to reduce bleeding following ESD, including SLE, and the high-risk patients SLE will benefit most will be discussed.

***SLE after endoscopic submucosal dissection***

Delayed bleeding still occurs in approximately 5% of patients who have undergone gastric ESD, despite proton pump inhibitor (PPI) neutralization of intragastric acidity and endoscopic hemostasis through prophylactic coagulation of visible vessels at the ulcer base[[3](#_ENREF_3),[5](#_ENREF_5),[10-12](#_ENREF_10)]. SLE is generally defined as repeat endoscopy within 24 hours after the initial endoscopy and hemostatic therapy. For the management of peptic ulcer bleeding, routine SLE is not recommended following successful endoscopic hemostasis. Repeat endoscopy should be performed on patients with clinical evidence of recurrent bleeding. Hemostatic therapy should furthermore be applied to patients with higher risk stigmata of hemorrhage[[13](#_ENREF_13)]. For the perioperative management of post-ESD bleeding, the benefit of SLE remains controversial. However, routine SLE continues to be performed in many medical centers which have inpatients-based ESD treatment setting, probably because the delayed bleeding rate overall remains at approximately 5%[[9](#_ENREF_9)]. If high-risk ulcer stigmata after ESD are treated only using PPI without endoscopic therapy, the bleeding risk might be higher, and more serious complication may develop following discharge. Recently, the efficacy of SLE for ESD induced ulcers was evaluated in several retrospective studies and three prospective randomized trials[[8](#_ENREF_8),[14-17](#_ENREF_14)] (Table 1). The results indicated that the incidence of post-ESD bleeding was not significantly affected by SLE. However, three prospective studies had several limitations that should be taken into account. Ryu HY *et al*[17] reported that 12 patients (16.2%) in the SLE group and 9 (11.1%) in the no SLE group experienced bleeding after ESD (*P* = 0.66). The delayed bleeding was defined as the presence of any symptoms or signs of bleeding such as melena or hematemesis from 2 to 28 d. This definition can include the past bleeding episode and other site bleeding, therefore, it may be the reason of higher incidence of bleeding than other studies. The number of enrolled patients was smaller than the calculated sample size, it might be under powered to assess their statistics between two groups. Kim JS *et al*[15] demonstrated that delayed bleeding occurred in 8 lesions (3.6%) receiving a SLE and 6 (2.8%) not receiving a SLE (*P* = 0.79). Delayed bleeding was defined as bleeding at 3 to 56 d requiring emergency hemostasis for bleeding on artificial ulcer sites because of hematemesis, melena, hematochezia. The sample sized was not calculated statistically in this study. Mochizuki S *et al*[8] reported that post-ESD bleeding occurred in 7 patients (5.4%) with SLE and five patients with (3.8%) non-SLE [95% confidence interval (CI): -6.7 to 3.5]; meeting the non-inferiority criterion (7%). Delayed bleeding was defined as hemorrhage confirmed by emergency endoscopy from the time of the completion of ESD to 28 d and showed clinical symptoms including hematemesis, melena or a decrease in hemoglobin of > 2 g/dL. The sample sized was adequately calculated for the assessment of non-inferiority of the non-SLE compared with the SLE. The limitation of three randomized controlled trial (RCT) was different definitions of delayed bleeding used. In addition, the patients taking antiplatelet or anticoagulant drug during the perioperative period were excluded in all three RCT. Is it possible to conclude that the SLE is no longer necessary following gastric ESD? Unfortunately the results remain inconclusive, as the studies so far have been performed only on relatively small cohorts.

Most delayed bleeding events have been shown to occur within the first 24 to 48 hours, but remained a possibility for up to 2 wk following ESD. In many institutions, SLE was routinely carried out within 1-2 d following ESD as a precaution against the more serious clinical outcomes for delayed bleeding[[9](#_ENREF_9)]. The potential advantage of routine SLE is that the procedure can be used to evaluate the status of healing ulcers and to perform additional hemostasis if necessary. However, there are arguments concerning the cost/benefit of SLE for ESD ulcers as well as peptic ulcers. If a subgroup of patients at high risk for recurrent bleeding following ESD could be identified, this group potentially could derive benefit from SLE. Risk factors leading to postoperative bleeding remain controversial however because the perioperative management of gastric ESD has not been standardized. Although several factors are reported to be associated with an increased risk of delayed bleeding after ESD, none have been identified that reliably detect a high-risk population. It is therefore possible that risk factors for bleeding following ESD originate from technical parameters which are more difficult to assess objectively.

***Role of proton-pump inhibitors in the prevention of bleeding events***

Intraoperative bleeding is an unavoidable consequence during mucosal incision or submucosal dissections. Thus, most endoscopist never consider intraoperative bleeding as a complication except in cases requiring emergency surgery or blood transfusion, or in cases where ESD is discontinued because of bleeding[[18](#_ENREF_18)].

One strategy to control bleeding is to regulate intra-gastric acidity, as intragastric pH above 5.4 facilitates blood coagulation and platelet aggregation[[19](#_ENREF_19)]. In order to achieve this pH level, PPI is more effective than of H2RA. Previous meta-analysis result compared with PPI *vs* H2RA for the management of iatrogenic gastric ulcer after EMR or ESD showed that PPIs are more effective than H2RA[[20](#_ENREF_20)]. Therefore, PPI infusion therapy is routinely used to prevent bleeding and promote ulcer healing following ESD in most institutions. But, recent randomized controlled studies showed conflicting results that H2RA was comparable healing rate and delayed bleeding rate[[21-25](#_ENREF_21)].

Pre-endoscopic intravenous PPI therapy in peptic ulcer bleeding, which inhibits production of gastric acid, significantly reduces the incidence of bleeding at higher risk stigmata of hemorrhage, such as active bleeding, non-bleeding visible vessels, and adherent clots[[26](#_ENREF_26)]. However, the effectiveness of preoperative administration of PPI in the management of artificial ulcers following ESD remains unclear. As raising intra-gastric pH preoperatively may lead to easy and complete endoscopic hemostasis during ESD and increases blood coagulation of iatrogenic ulcers, a randomized study has been conducted to determine the effectiveness of preoperative administration of a PPI for the prevention of bleeding. A trial of 24-hour pre-administration of omeprazole increased intra-gastric pH at the time of ESD[[27](#_ENREF_27)]. However, results demonstrated no additional beneﬁt of a higher intra-gastric pH in the prevention of bleeding, including intraoperative and post-operative delayed bleeding following the procedure.

Because intraoperative bleeding is generally characterized as spurting or oozing, a high intra-gastric pH might not be an effective preventive measure against intraoperative bleeding. In our opinion, the occurrence of intraoperative bleeding may be related not only to measurable risk factors, such as size of resected specimen and location, but also to unquantifiable technical factors, such as electrosurgical unit settings, the type of electrosurgical knife, injection solutions, and experience of the operator[[18](#_ENREF_18),[28](#_ENREF_28)]. Furthermore, this study was complicated by the fact that all patients in the study groups had been administered a regular dose of PPI for 4 wk. Thus, short course pre-operative administration of PPI might not be sufficient to produce a difference in the incidence of delayed bleeding events.

***Prophylactic coagulation of visible vessel at the ulcer base following ESD***

Recent guidelines for the management of peptic ulcer bleeding suggest that endoscopic therapy should be provided to patients with a non-bleeding visible vessel[[13](#_ENREF_13),[29](#_ENREF_29)]. In addition, endoscopic therapy may be considered for patients with an adherent clot resistant to vigorous irrigation. Furthermore, the benefit of endoscopy may be greater for patients with clinical features associated with a higher risk of rebleeding, such as older age, concurrent illness, and inpatient status at occurrence[[13](#_ENREF_13)]. For the management of artificial ulcers generated during ESD, prophylactic coagulation of exposed visible vessels at the base of a mucosal defect following ESD was shown to lead to a reduction in the incidence of bleeding (7.1% *vs* 3.1%; *P* < 0.01)[[5](#_ENREF_5)]. Routine coagulation of all non-bleeding visible vessels at the ulcer base is thus performed as standard practice. However, both prophylactic coagulation of all visible vessels at the ulcer bed and administration of PPIs do not completely eliminate the possibility of delayed bleeding (Table 2).

***Patient-related risk factors associated with delayed bleeding***

Most studies reported large resected specimen size to be an independent risk factor for delayed bleeding[[10](#_ENREF_10),[12](#_ENREF_12),[30](#_ENREF_30)] (Table 2). Theoretically, a large lesion has a more expansive vascular network than a small lesion, which enhances the possibility of bleeding during and following ESD.

Still, risks of lesion location were variable. Intraoperative bleeding risk was reported to be higher in the upper region than in the middle and lower regions of the stomach. Arteries in the submucosal layer of the upper stomach are significantly thicker or more stubby than in other gastric sites, and the diameter of submucosal arteries is larger in the upper area than in the middle or lower stomach[[5](#_ENREF_5)]. Therefore, the risk of intraoperative bleeding is greater in the upper stomach, and intraoperative hemostasis is more frequently necessary during removal of a lesion in this region. In contrast, a delayed bleeding risk was reported to be greater in the lower region of the stomach[[5](#_ENREF_5)]. In other words, while intraoperative hemostasis is less frequently necessary in the middle and lower gastric regions, bleeding may still occur here later if vessels in these areas are not coagulated at the time of procedure. The occurrence of delayed bleeding might not have been due to insufficient hemostasis, but rather to insufficient coagulation during resection, because the sites where delayed bleeding occurred were different than those where immediate bleeding has been controlled endoscopically[[31](#_ENREF_31)]. Antral peristaltic activity and bile juice reflux might also contribute to some degree.

The Forrest classification provides prognostic information regarding the risk of rebleeding, and the need for therapeutic intervention in ulcer disease. Endoscopic therapy is indicated for patients with high-risk ulcer stigmata (Forrest type I and IIa). For this reason, additional hemostasis for high-risk ulcer stigmata may decrease the chance of further bleeding and/or emergency intervention. In a prospective observation study, submucosal fibrosis [odds ratios (OR) = 3.91; 95%CI = 1.92-7.94] and nausea after ESD (OR = 4.76; 95%CI = 2.39-9.43) were risk factors significantly associated with high-risk ulcers[[3](#_ENREF_3)]. To resect submucosal fibrosis, deeper submucosal dissection is generally necessary, but superficial proper muscle damage might occur. Such manipulation of the tissue might lead to the development of ulcers with a high-risk of bleeding. Furthermore, the lesions with more submucosal vessels may require more frequent coagulation during ESD. This treatment may result in coagulation-induced gastric edema and a more intense inflammatory response, which will cause nausea. A significant amount of blood from an artificial ulcer can also induce nausea. In fact, despite additive coagulation in patients with high-risk ulcer stigmata, the rebleeding incidence on SLE was 8.6% relative to patients with low-risk stigmata. A potential explanation is that ulcers at high risk for bleeding tend to also be rich in vascularity.

***Drug-related risk factors for delayed bleeding***

An increasing number of patients are taking multiple antiplatelet medications or antithrombotic drugs as the incidence of cardiovascular disease rises. Antiplatelet or antithrombotic medications to prevent cardiovascular events in patients present an additional concern, as ESD is a procedure with high risk of bleeding. Most endoscopists prefer to interrupt the use of antiplatelet or antithrombotic drugs for as long as possible. In one retrospective observational study, continuous administration of antiplatelet medication was not found to be a signiﬁcantly associated with bleeding[[32](#_ENREF_32)] (OR = 1.596; 95%CI = 0.877-2.903; *P* =0.126), whereas in another retrospective study, the use of aspirin by itself was associated with post-ESD bleeding[[33](#_ENREF_33)] (OR = 4.49; 95%CI = 1.09-18.38). In the latter, the resumption specifically of clopidogrel combined with aspirin use (OR = 26.71; 95%CI = 7.09-100.53) was significantly associated with post-ESD bleeding. In recent two retrospective studies to evaluate the hemorrhagic risk of ESD in patients on antiplatelet drug, Tounou S *et al*[[34](#_ENREF_34)] demonstrated that dual antiplatelet therapy markedly increased the risk for bleeding (hazard ratio = 16.3; 95%CI = 3.4-78.2), but continuous low dose aspirin does not. Sanomura Y *et al*[[35](#_ENREF_35)] also reported that continued use of low dose aspirin does not increased the risk of bleeding during or after ESD. In a recent prospective study, subanalysis of gastric ESD showed that administration of thienopyridine derivatives (*P* = 0.01) and multiple antiplatelet agents (*P* = 0.02) were significant contributing factors to bleeding[[36](#_ENREF_36)] (Table 3), but the continuation of aspirin alone appeared to be acceptable.

In general, post-ESD bleeding in patients taking aspirin can be managed effectively without increasing long-term morbidity or mortality. However, cerebral infarction upon discontinuation of aspirin intake is a critical complication. Therefore, ASGE and ESGE and JGES guideline recommend low dose aspirin should be continued for endoscopic treatment with high bleeding risk when the risk of thromboembolism is high[[37-39](#_ENREF_37)]. Taken together, the results indicate that if a patient has a low risk for a thromboembolic event, aspirin use should be ceased. However, if a patient has a high risk for thromboembolism, aspirin may be continued as a thromboembolic event could otherwise result in more serious consequences affecting quality of life.

**CONCLUSION**

Bleeding is a major potential complication both during and post-ESD. Decreased incidence of delayed bleeding is associated with the use of anti-secretory agents, especially PPI, and prophylactic coagulation of visible vessels at the ulcer base following ESD. However, despite these therapeutic interventions, delayed bleeding still occurs in approximately 5% of patients who undergo gastric ESD. To date, SLE after ESD has been a common therapeutic strategy in order to avoid a bleeding event. The results of recent randomized studies however were unfavorable for routine SLE after gastric ESD. Although routine SLE for all patients after gastric ESD might be unnecessary, SLE may be an important tool in the treatment of a subgroup of patients at risk for bleeding or high-risk ulcer stigmata. Well-known potential risk factors of delayed bleeding are large size of resected specimen and treatment with multiple antiplatelet agents. Submucosal fibrosis and nausea after ESD might be associated with high-risk ulcer stigmata. Thus, these factors can be considered as indications for the use of SLE following ESD. To establish the optimal perioperative strategies for safe ESD, well-designed prospective studies should be conducted in the future to more clearly identify at risk patients.

**REFERENCES**

1. **Min BH**, Lee JH, Kim JJ, Shim SG, Chang DK, Kim YH, Rhee PL, Kim KM, Park CK, Rhee JC. Clinical outcomes of endoscopic submucosal dissection (ESD) for treating early gastric cancer: comparison with endoscopic mucosal resection after circumferential precutting (EMR-P). *Dig Liver Dis* 2009; **41**: 201-209 [PMID: 18571998 DOI: 10.1016/j.dld.2008.05.006]
2. **Oka S**, Tanaka S, Kaneko I, Mouri R, Hirata M, Kawamura T, Yoshihara M, Chayama K. Advantage of endoscopic submucosal dissection compared with EMR for early gastric cancer. *Gastrointest Endosc* 2006; **64**: 877-883 [PMID: 17140890 DOI: 10.1016/j.gie.2006.03.932]
3. **Choi CW**, Kim HW, Kang DH, Hong YM, Kim SJ, Park SB, Cho M, Kim DJ, Hong JB. Clinical outcomes of second-look endoscopy after gastric endoscopic submucosal dissection: predictive factors with high risks of bleeding. *Surg Endosc* 2014; **28**: 2213-2220 [PMID: 24570014 DOI: 10.1007/s00464-014-3457-2]
4. **Nakamura M**, Nishikawa J, Hamabe K, Nishimura J, Satake M, Goto A, Kiyotoki S, Saito M, Fukagawa Y, Shirai Y, Okamoto T, Sakaida I. Risk factors for delayed bleeding from endoscopic submucosal dissection of gastric neoplasms. *Scand J Gastroenterol* 2012; **47**: 1108-1114 [PMID: 22783937 DOI: 10.3109/00365521.2012.699550]
5. **Takizawa K**, Oda I, Gotoda T, Yokoi C, Matsuda T, Saito Y, Saito D, Ono H. Routine coagulation of visible vessels may prevent delayed bleeding after endoscopic submucosal dissection--an analysis of risk factors. *Endoscopy* 2008; **40**: 179-183 [PMID: 18322872 DOI: 10.1055/s-2007-995530]
6. **Goto O**, Fujishiro M, Kodashima S, Ono S, Niimi K, Hirano K, Yamamichi N, Koike K. A second-look endoscopy after endoscopic submucosal dissection for gastric epithelial neoplasm may be unnecessary: a retrospective analysis of postendoscopic submucosal dissection bleeding. *Gastrointest Endosc* 2010; **71**: 241-248 [PMID: 19922919 DOI: 10.1016/j.gie.2009.08.030]
7. **Ohkuwa M**, Hosokawa K, Boku N, Ohtu A, Tajiri H, Yoshida S. New endoscopic treatment for intramucosal gastric tumors using an insulated-tip diathermic knife. *Endoscopy* 2001; **33**: 221-226 [PMID: 11293753 DOI: 10.1055/s-2001-12805]
8. **Mochizuki S**, Uedo N, Oda I, Kaneko K, Yamamoto Y, Yamashina T, Suzuki H, Kodashima S, Yano T, Yamamichi N, Goto O, Shimamoto T, Fujishiro M, Koike K. Scheduled second-look endoscopy is not recommended after endoscopic submucosal dissection for gastric neoplasms (the SAFE trial): a multicentre prospective randomised controlled non-inferiority trial. *Gut* 2015; **64**: 397-405 [PMID: 25301853 DOI: 10.1136/gutjnl-2014-307552]
9. **Goto O**, Fujishiro M, Oda I, Kakushima N, Yamamoto Y, Tsuji Y, Ohata K, Fujiwara T, Fujiwara J, Ishii N, Yokoi C, Miyamoto S, Itoh T, Morishita S, Gotoda T, Koike K. A multicenter survey of the management after gastric endoscopic submucosal dissection related to postoperative bleeding. *Dig Dis Sci* 2012; **57**: 435-439 [PMID: 21901257 DOI: 10.1007/s10620-011-1886-5]
10. **Okada K**, Yamamoto Y, Kasuga A, Omae M, Kubota M, Hirasawa T, Ishiyama A, Chino A, Tsuchida T, Fujisaki J, Nakajima A, Hoshino E, Igarashi M. Risk factors for delayed bleeding after endoscopic submucosal dissection for gastric neoplasm. *Surg Endosc* 2011; **25**: 98-107 [PMID: 20549245 DOI: 10.1007/s00464-010-1137-4]
11. **Toyokawa T**, Inaba T, Omote S, Okamoto A, Miyasaka R, Watanabe K, Izumikawa K, Horii J, Fujita I, Ishikawa S, Morikawa T, Murakami T, Tomoda J. Risk factors for perforation and delayed bleeding associated with endoscopic submucosal dissection for early gastric neoplasms: analysis of 1123 lesions. *J Gastroenterol Hepatol* 2012; **27**: 907-912 [PMID: 22142449 DOI: 10.1111/j.1440-1746.2011.07039.x]
12. **Koh R**, Hirasawa K, Yahara S, Oka H, Sugimori K, Morimoto M, Numata K, Kokawa A, Sasaki T, Nozawa A, Taguri M, Morita S, Maeda S, Tanaka K. Antithrombotic drugs are risk factors for delayed postoperative bleeding after endoscopic submucosal dissection for gastric neoplasms. *Gastrointest Endosc* 2013; **78**: 476-483 [PMID: 23622974 DOI: 10.1016/j.gie.2013.03.008]
13. **Laine L**, Jensen DM. Management of patients with ulcer bleeding. *Am J Gastroenterol* 2012; **107**: 345-60; quiz 361 [PMID: 22310222 DOI: 10.1038/ajg.2011.480]
14. **Park CH**, Park JC, Lee H, Shin SK, Lee SK, Lee YC. Second-look endoscopy after gastric endoscopic submucosal dissection for reducing delayed postoperative bleeding. *Gut Liver* 2015; **9**: 43-51 [PMID: 25170062 DOI: 10.5009/gnl13252]
15. **Kim ER**, Kim JH, Kang KJ, Min BH, Lee JH, Rhee PL, Rhee JC, Kim JJ. Is a second-look endoscopy necessary after endoscopic submucosal dissection for gastric neoplasm? *Gut Liver* 2015; **9**: 52-58 [PMID: 25071070 DOI: 10.5009/gnl13422]
16. **Kim JS**, Chung MW, Chung CY, Park HC, Ryang DY, Myung DS, Cho SB, Lee WS, Joo YE. The need for second-look endoscopy to prevent delayed bleeding after endoscopic submucosal dissection for gastric neoplasms: a prospective randomized trial. *Gut Liver* 2014; **8**: 480-486 [PMID: 25228971 DOI: 10.5009/gnl13226]
17. **Ryu HY**, Kim JW, Kim HS, Park HJ, Jeon HK, Park SY, Kim BR, Lang CC, Won SH. Second-look endoscopy is not associated with better clinical outcomes after gastric endoscopic submucosal dissection: a prospective, randomized, clinical trial analyzed on an as-treated basis. *Gastrointest Endosc* 2013; **78**: 285-294 [PMID: 23531425 DOI: 10.1016/j.gie.2013.02.008]
18. **Fujishiro M**, Chiu PW, Wang HP. Role of antisecretory agents for gastric endoscopic submucosal dissection. *Dig Endosc* 2013; **25 Suppl 1**: 86-93 [PMID: 23368844 DOI: 10.1111/j.1443-1661.2012.01370.x]
19. **Green FW**, Kaplan MM, Curtis LE, Levine PH. Effect of acid and pepsin on blood coagulation and platelet aggregation. A possible contributor prolonged gastroduodenal mucosal hemorrhage. *Gastroenterology* 1978; **74**: 38-43 [PMID: 21830]
20. **Yang Z**, Wu Q, Liu Z, Wu K, Fan D. Proton pump inhibitors versus histamine-2-receptor antagonists for the management of iatrogenic gastric ulcer after endoscopic mucosal resection or endoscopic submucosal dissection: a meta-analysis of randomized trials. *Digestion* 2011; **84**: 315-320 [PMID: 22075541 DOI: 10.1159/000331138]
21. **Imaeda H**, Hosoe N, Suzuki H, Saito Y, Ida Y, Nakamura R, Iwao Y, Ogata H, Hibi T. Effect of lansoprazole versus roxatidine on prevention of bleeding and promotion of ulcer healing after endoscopic submucosal dissection for superficial gastric neoplasia. *J Gastroenterol* 2011; **46**: 1267-1272 [PMID: 21805066 DOI: 10.1007/s00535-011-0447-1]
22. **Jeong HK**, Park CH, Jun CH, Lee GH, Kim HI, Kim HS, Choi SK, Rew JS. A prospective randomized trial of either famotidine or pantoprazole for the prevention of bleeding after endoscopic submucosal dissection. *J Korean Med Sci* 2007; **22**: 1055-1059 [PMID: 18162722 DOI: [10.3346/jkms.2007.22.6.1055](http://dx.doi.org/10.3346/jkms.2007.22.6.1055%22%20%5Ct%20%22_blank)]
23. **Ohya TR**, Endo H, Kawagoe K, Yanagawa T, Hanawa K, Ohata K, Asayama M, Hisatomi K, Teratani T, Gunji T, Sato H, Matsuhashi N. A prospective randomized trial of lafutidine vs rabeprazole on post-ESD gastric ulcers. *World J Gastrointest Endosc* 2010; **2**: 36-40 [PMID: 21160677 DOI: 10.4253/wjge.v2.i1.36]
24. **Tomita T**, Kim Y, Yamasaki T, Okugawa T, Kondo T, Toyoshima F, Sakurai J, Tanaka J, Morita T, Oshima T, Fukui H, Hori K, Watari J, Matsumoto T, Miwa H. Prospective randomized controlled trial to compare the effects of omeprazole and famotidine in preventing delayed bleeding and promoting ulcer healing after endoscopic submucosal dissection. *J Gastroenterol Hepatol* 2012; **27**: 1441-1446 [PMID: 22497427 DOI: 10.1111/j.1440-1746.2012.07144.x]
25. **Uedo N**, Takeuchi Y, Yamada T, Ishihara R, Ogiyama H, Yamamoto S, Kato M, Tatsumi K, Masuda E, Tamai C, Yamamoto S, Higashino K, Iishi H, Tatsuta M. Effect of a proton pump inhibitor or an H2-receptor antagonist on prevention of bleeding from ulcer after endoscopic submucosal dissection of early gastric cancer: a prospective randomized controlled trial. *Am J Gastroenterol* 2007; **102**: 1610-1616 [PMID: 17403076 DOI: 10.1111/j.1572-0241.2007.01197.x]
26. **Lau JY**, Leung WK, Wu JC, Chan FK, Wong VW, Chiu PW, Lee VW, Lee KK, Cheung FK, Siu P, Ng EK, Sung JJ. Omeprazole before endoscopy in patients with gastrointestinal bleeding. *N Engl J Med* 2007; **356**: 1631-1640 [PMID: 17442905 DOI: 10.1056/NEJMoa065703]
27. **Ono S**, Kato M, Ono Y, Nakagawa M, Nakagawa S, Shimizu Y, Asaka M. Effects of preoperative administration of omeprazole on bleeding after endoscopic submucosal dissection: a prospective randomized controlled trial. *Endoscopy* 2009; **41**: 299-303 [PMID: 19340731 DOI: 10.1055/s-0029-1214530]
28. **Jeon SW**, Jung MK, Cho CM, Tak WY, Kweon YO, Kim SK, Choi YH. Predictors of immediate bleeding during endoscopic submucosal dissection in gastric lesions. *Surg Endosc* 2009; **23**: 1974-1979 [PMID: 18553202 DOI: 10.1007/s00464-008-9988-7]
29. **Hwang JH**, Fisher DA, Ben-Menachem T, Chandrasekhara V, Chathadi K, Decker GA, Early DS, Evans JA, Fanelli RD, Foley K, Fukami N, Jain R, Jue TL, Khan KM, Lightdale J, Malpas PM, Maple JT, Pasha S, Saltzman J, Sharaf R, Shergill AK, Dominitz JA, Cash BD. The role of endoscopy in the management of acute non-variceal upper GI bleeding. *Gastrointest Endosc* 2012; **75**: 1132-1138 [PMID: 22624808 DOI: 10.1016/j.gie.2012.02.033]
30. **Chung IK**, Lee JH, Lee SH, Kim SJ, Cho JY, Cho WY, Hwangbo Y, Keum BR, Park JJ, Chun HJ, Kim HJ, Kim JJ, Ji SR, Seol SY. Therapeutic outcomes in 1000 cases of endoscopic submucosal dissection for early gastric neoplasms: Korean ESD Study Group multicenter study. *Gastrointest Endosc* 2009; **69**: 1228-1235 [PMID: 19249769 DOI: 10.1016/j.gie.2008.09.027]
31. **Okano A**, Hajiro K, Takakuwa H, Nishio A, Matsushita M. Predictors of bleeding after endoscopic mucosal resection of gastric tumors. *Gastrointest Endosc* 2003; **57**: 687-690 [PMID: 12709698 DOI: 10.1067/mge.2003.192]
32. **Lim JH**, Kim SG, Kim JW, Choi YJ, Kwon J, Kim JY, Lee YB, Choi J, Im JP, Kim JS, Jung HC, Song IS. Do antiplatelets increase the risk of bleeding after endoscopic submucosal dissection of gastric neoplasms? *Gastrointest Endosc* 2012; **75**: 719-727 [PMID: 22317881 DOI: 10.1016/j.gie.2011.11.034]
33. **Cho SJ**, Choi IJ, Kim CG, Lee JY, Nam BH, Kwak MH, Kim HJ, Ryu KW, Lee JH, Kim YW. Aspirin use and bleeding risk after endoscopic submucosal dissection in patients with gastric neoplasms. *Endoscopy* 2012; **44**: 114-121 [PMID: 22271021 DOI: 10.1055/s-0031-1291459]
34. **Tounou S**, Morita Y, Hosono T. Continuous aspirin use does not increase post-endoscopic dissection bleeding risk for gastric neoplasms in patients on antiplatelet therapy. *Endosc Int Open* 2015; **3**: E31-E38 [PMID: 26134769 DOI: 10.1055/s-0034-1390764]
35. **Sanomura Y**, Oka S, Tanaka S, Numata N, Higashiyama M, Kanao H, Yoshida S, Ueno Y, Chayama K. Continued use of low-dose aspirin does not increase the risk of bleeding during or after endoscopic submucosal dissection for early gastric cancer. *Gastric Cancer* 2014; **17**: 489-496 [PMID: 24142107 DOI: 10.1007/s10120-013-0305-3]
36. **Ono S**, Fujishiro M, Yoshida N, Doyama H, Kamoshida T, Hirai S, Kishihara T, Yamamoto Y, Sakae H, Imagawa A, Hirano M, Koike K. Thienopyridine derivatives as risk factors for bleeding following high risk endoscopic treatments: Safe Treatment on Antiplatelets (STRAP) study. *Endoscopy* 2015; **47**: 632-637 [PMID: 25590184 DOI: 10.1055/s-0034-1391354]
37. **Anderson MA**, Ben-Menachem T, Gan SI, Appalaneni V, Banerjee S, Cash BD, Fisher L, Harrison ME, Fanelli RD, Fukami N, Ikenberry SO, Jain R, Khan K, Krinsky ML, Lichtenstein DR, Maple JT, Shen B, Strohmeyer L, Baron T, Dominitz JA. Management of antithrombotic agents for endoscopic procedures. *Gastrointest Endosc* 2009; **70**: 1060-1070 [PMID: 19889407 DOI: 10.1016/j.gie.2009.09.040]
38. **Boustière C**, Veitch A, Vanbiervliet G, Bulois P, Deprez P, Laquiere A, Laugier R, Lesur G, Mosler P, Nalet B, Napoleon B, Rembacken B, Ajzenberg N, Collet JP, Baron T, Dumonceau JM. Endoscopy and antiplatelet agents. European Society of Gastrointestinal Endoscopy (ESGE) Guideline. *Endoscopy* 2011; **43**: 445-461 [PMID: 21547880 DOI: 10.1055/s-0030-1256317]
39. **Fujimoto K**, Fujishiro M, Kato M, Higuchi K, Iwakiri R, Sakamoto C, Uchiyama S, Kashiwagi A, Ogawa H, Murakami K, Mine T, Yoshino J, Kinoshita Y, Ichinose M, Matsui T. Guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment. *Dig Endosc* 2014; **26**: 1-14 [PMID: 24215155 DOI: 10.1111/den.12183]

**P-Reviewer:** Abe S, Kiriyama S **S-Editor:** Kong JX **L-Editor:** **E-Editor:**

 **Table 1 Influence of second-look endoscopy on the incidence of bleeding following endoscopic submucosal dissection**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Author** | **Year** | ***n*** | **Study Design** | **Bleeding:SLE *vs* no SLE (%)** | **Risk factors for delayed bleeding** | **SLE benefit** |
| Ryu *et al*[[17](#_ENREF_17)] | 2013 | 182 | Prospective, single center | 16.2% *vs* 11.1% | No risk factors | no |
| Mochizuki S *et al*[[8](#_ENREF_8)] | 2014 | 262 | Prospective, Multicenter center | 5.4% *vs* 3.8% | Resected specimen size > 40 mm | no |
| Kim *et al*[[16](#_ENREF_16)] | 2014 | 437 | Prospective, single center | 3.6% *vs* 2.8% | Large tumor size (> 20 mm) | no |
| Park *et al*[[14](#_ENREF_14)] | 2015 | 445 | Retrospective | 3.0% *vs* 2.0% | Tumor in the upper-third of the stomach,resected specimen size > 40 mm | no |
| Kim *et al*[[15](#_ENREF_15)] | 2015 | 502 | Retrospective | 1.0% *vs* 2.5% | Large tumor size (> 15 mm) | no |

SLE: Second-look endoscopy.

**Table 2 Incidence of delayed bleeding and associated risk factors after gastric endoscopic submucosal dissection**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Author** | **Year** | ***n*** | **Study Design** | **Bleeding (%)** | **Risk factors** | **Remarks** |
| Takizawa *et al*[[5](#_ENREF_5)] | 2008 | 968 | Retrospective | 5.8% (7.1% *vs* 3.1% with PEC) | Tumor location in middle and lower regions of the stomach, PEC | PEC of visible vessels in the resected area follwing ESD may lead to a decreased bleeding rate |
| Chung *et al*[[30](#_ENREF_30)] | 2009 | 952 | Retrospective | 15.60% | Upper region, size of the tumor (> 40 mm), recurrent lesion, flat morphology | A signiﬁcant bleeding incidence was at 0.6% |
| Okada *et al*[[10](#_ENREF_10)] | 2011 | 582 | Retrospective | 4.81% | Resected specimen width (≥ 40 mm) | Mechanism of delayed bleeding may differ depending on the time elapsed between ESD and bleeding episodes |
| Toyokawa *et al*[[11](#_ENREF_11)] | 2012 | 1123 | Retrospective | 5.00% | Age ≥ 80 yr,extended duration of procedure | - |
| Goto *et al*[[9](#_ENREF_9)] | 2012 | 1814 | Retrospective | 5.50% | No statistical parameters | Multicenter survey clariﬁed that post-ESD management (duration of PPI use, resumption of food intake, and performance of SLE) varied among the medical centers |
| Koh *et al*[[12](#_ENREF_12)] | 2013 | 1032 | Retrospective | 5.30% | Size of resected specimen(> 40 mm), use of antithrombotic drugs (only for delay bleeding) | The incidence of delayed bleeding in patients with two risk factors was 11.6%. |
| Choi *et al*[[3](#_ENREF_3)] | 2014 | 614 | Prospective observation | Early (3.7%) Late (1.9%) | Surface erosion, high risk of stigmata during SLE, location in the middle of the stomach | Nausea and submucosal fibrosis increase the incidence of high risk of stigmata in SLE |

PEC: Post-endoscopic submucosal dissection coagulation; ESD: Endoscopic submucosal dissection; PPI: Proton pump inhibitor; SLE: Second-look endoscopy.

**Table 3 Antiplatelet medication and the risk of delayed bleeding**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Author** | **Year** | ***n*** | **Design** | **Method** | **Comparison of bleeding incidence** | **Comments** |
| Lim *et al*[[32](#_ENREF_32)] | 2012 | 1591 | Retrospective | ESD | No antiplatelet medication: 5.2%Antiplatelet withdrawal: 5.9% Antiplatelet continuation: 11.6% | Continuous administration of antiplatelet medication was not found to have an independent significant association with bleeding |
| Cho *et al*[[33](#_ENREF_33)] | 2012 | 514 | Retrospective | ESD | No aspirin medication: 3.4%Aspirin withdrawal: 3.6%Aspirin continuation: 21.1% | Continuous aspirin use increases the risk of bleeding after gastric ESD |
| Sanomura *et al*[[35](#_ENREF_35)] | 2014 | 94 | Retrospective | ESD | Aspirin interruption: 7.1%Aspirin continuation: 4.8% | Continued use of aspirin does not increase the risk of bleeding during or after ESD |
| Tounou *et al*[[34](#_ENREF_34)] | 2015 | 377 | Retrospective | ESD | No aspirin medication: 6.1%Aspirin continuation: 14.4%Single antiplatelet: 15.5%Dual antiplatelet: 35.5% | Aspirin was not a significant risk foctor for post-ESD bleeding |
| Ono *et al*[[36](#_ENREF_36)] | 2015 | 28 | Prospective,observational | ESD/EMR | The study was terminated in accordance with predetermined safety criteria because 7 of 28 consecutive patients experienced major bleeding complications (25.0%) | Subanalysis of gastric ESD (23 lesions in 19 patients) confirmed that the administration of thienopyridine derivatives (*P* = 0.01) and multiple agents (*P* = 0.02) were the significant factorsContinuation of aspirin alone during these endoscopic procedures may be acceptable |

ESD: Endoscopic submucosal dissection; EMR: Endoscopic mucosal resection.